Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

CDK4/6 Inhibitor Combinations for HR+ mBC

October 2nd 2017

ER+/HER2+ Metastatic Breast Cancer

October 2nd 2017

Future Directions: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017

Treatment Selection for HR+ mBC

October 2nd 2017

mBC: CDK4/6 Inhibitor Patient Selection/Sequencing

October 2nd 2017

CDK4/6 Inhibitors in Breast Cancer: Ongoing Research

October 2nd 2017

FDA Approval for Abemaciclib

October 2nd 2017

MONARCH 3: Abemaciclib With Endocrine Therapy for mBC

October 2nd 2017

MONARCH 1: Abemaciclib Monotherapy for HR+ mBC

October 2nd 2017

Abemaciclib + Fulvestrant at Progression of HR+ mBC

October 2nd 2017

Abemaciclib for ER+ mBC

October 2nd 2017

CDK4/6 Inhibitors: Managing Toxicity in HR+ mBC

October 2nd 2017

Clinical Experience: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017

CDK 4/6 Inhibitors in Metastatic Breast Cancer

October 2nd 2017

Dr. Hoffman-Censits on Biomarker Development in Urothelial Carcinoma

September 29th 2017

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses biomarker development in the field of urothelial carcinoma.

PEGPH20 Offers New Mechanism for Attacking Pancreas Tumors

September 29th 2017

PEGPH20 (pegvorhyaluronidase alfa), a novel formulation of a naturally occuring enzyme, is being investigated as a biomarker-driven treatment for patients with advanced pancreatic cancer.

Lead FLAURA Researcher Discusses Frontline Osimertinib in EGFR+ NSCLC

September 29th 2017

Suresh A. Ramalingam, MD, discusses the practice-changing FLAURA findings and his thoughts on sequencing should the FDA approve osimertinib in the frontline setting of non-small cell lung cancer.

Future Directions in NSCLC Immuno-Oncology Research

September 28th 2017

Immuno-Oncology Combination Therapy in NSCLC

September 28th 2017

Promising Immunotherapy Agents for NSCLC

September 28th 2017